Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEPDOWNmHSPC: De-escalation to ADT Alone vs Continuation of Doublet/Triplet Therapy in mHSPC
NCT07838753Phase 2Not yet recruiting
- Sponsor
- Kokilaben Dhirubhai Ambani Hospital
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) (2 arms), sponsored by Kokilaben Dhirubhai Ambani Hospital. Primary endpoints: Radiographic Progression-Free Survival at 18 months and PSA Progression-Free Survival up to 60 months. Planned start Sep 2026; status: not yet recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07838753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07838753.